Received Nov 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
Rash; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of rash in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Previously administered products included Shingrix with an associated reaction of rash (1st dose received on an unknown date). On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, 2 months after receiving Shingles vaccine, the patient experienced rash (Verbatim: Rash). Rechallenge with Shingles vaccine was positive. The outcome of the rash was not reported. The reporter considered the rash to be unrelated to Shingles vaccine. The company considered the rash to be unrelated to Shingles vaccine. Linked case(s) involving the same patient: US2025AMR153465 Additional Information: GSK Receipt Date: 26-NOV-2025 This case was reported by a patient via interactive digital media. Patient had received her shingles shot when he/she aged into [withheld insurance] in 2024. Patient developed a rash about two months afterward. The doctor said it had nothing to do with the vaccine and patient disagreed. Patient had never had a rash before that, nor since. They said shingles had been worse and patient could agree with that. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: US-GSK-US2025AMR153465:Case for 1st dose/Same patient